Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone

Vermeire, An; Remon, Jean Paul

doi:10.1016/s0378-5173(98)00264-6

Cited by 17 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reasonable to expect that mixing of stock midazolam 5 mg/mL into CSF-like solutions buffered at approximately 7.3 could also lead to precipitation (cloudiness) (45) if the resulting concentrations are incompatible with the resulting less acidic pH. It should be further stressed that the use of multiple adjuvants can have untoward interactions regarding formulation stability (46). Drug admixtures with midazolam in general have not been well studied, and the likelihood of unfavorable interactions must be anticipated until proven otherwise.…”

Section: Midazolam Formulationmentioning

confidence: 97%

The Use of Intrathecal Midazolam in Humans: A Case Study of Process

Yaksh

Allen

2004

Anesthesia & Analgesia

View full text Add to dashboard Cite

show abstract

Section: Midazolam Formulationmentioning

confidence: 97%

The Use of Intrathecal Midazolam in Humans: A Case Study of Process

Yaksh

Allen

2004

Anesthesia & Analgesia

View full text Add to dashboard Cite

show abstract

“…The physical compatibility and/or stability of morphine combined with adjuvant drugs in solution destined to subcutaneous infusion has been widely studied [11,12,13,14,15,16,17,18,19,20] although in some studies only visual inspection of the samples was performed, providing information on the physical compatibility but not on the chemical compatibility or chemical stability of the drugs in the mixture. Moreover, studies have not yet been done regarding the combination of morphine hydrochloride and hyoscine-N-butyl bromide in solution in which the quantification of both drugs was performed by HPLC.…”

Section: Introductionmentioning

confidence: 99%

Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide

Barcia

Reyes

Azuara

et al. 2004

Support Care Cancer

View full text Add to dashboard Cite

The aim of this study was to determine the compatibility and stability of morphine hydrochloride and hyoscine-N-butyl bromide combined in solution at three different concentrations and stored in polypropylene syringes at 4 degrees C and 25 degrees C over a period of 15 days. The doses assayed were 20, 60 and 120 mg/day for morphine hydrochloride and 40, 60 and 80 mg/day for hyoscine-N-butyl bromide. These dose ranges were chosen according to daily practice. At both temperatures, all mixtures can be considered as physically compatible since no evidence of incompatibility-that is precipitation, turbidity, colour change or opacity and gas production-were observed. After 15 days of storage, the percentages of hyoscine-N-butyl bromide remaining in the drug mixtures tested ranged between 96.07% and 92.23%. At the end of the study, the percentages of morphine hydrochloride remaining in the drug mixtures were 100% at both temperatures.

show abstract

“…Vermeire et al developed methods to separate morphine-midazolam, morphine-haloperidol, and the degradation products of morphine, as well as haloperidol and midazolam (9). Vermeire et al developed methods to separate morphine-midazolam, morphine-haloperidol, and the degradation products of morphine, as well as haloperidol and midazolam (9).…”

Section: Stability Of Morphine Solutions 267mentioning

confidence: 99%

“…HPLC methods for determining the drugs involved in this study have already been reported (3)(4)(5)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23) …”

Section: Introductionmentioning

confidence: 99%

Hplc–dad Method for Studying the Stability of Solutions Containing Morphine, Dexamethasone, Haloperidol, Midazolam, Famotidine, Metoclopramide, and Dimenhydrinate

Nassr

Brunet

Lavoie³

et al. 2001

Journal of Liquid Chromatography & Related Technologies

View full text Add to dashboard Cite

The objectives of this study were to evaluate both the compatibility and the stability of morphine when mixed with different drugs and to provide recommendations for appropriate conservation conditions. Five drug mixtures used for palliative care were stored in polypropylene syringes at different temperatures (25 • C, 4 • C) up to 96 h. These mixtures were: 1) ORDER REPRINTS 266NASSR ET AL.Haloperidol, Famotidine, Metoclopramide, Dimenhydrinate. Drug mixtures were prepared in NaCl 0.9%, in order to obtain a 100 mL final solution containing the maximum daily dose of each component. For the separation and quantification of active ingredients, a fast, precise, accurate, and sensitive method was developed. Drugs were separated using HPLC-DAD (High performance liquid chromatography-diode array detector) with a Zorbax Eclipse XDB C 18 ) column under elution gradient. Just after preparing the mixture of drugs and then after 4,8,12,24, 48, 72, 96 h, the physical appearance of each solution was observed, and drug concentrations were controlled. Stability was assumed if the loss after 96 h was less than 10% of the initial concentration. Mixture number (2) was incompatible when drugs were mixed. Mixing haloperidol and dexamethasone gave rise to the formation of a white precipitate. Mixture (3) was stable and compatible at 25 • C, but incompatible at 4 • C due to crystallization of haloperidol. All the other drug mixtures were stable and compatible both at 4 • C and 25 • C for 96 h.

show abstract

Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone

Cited by 17 publications

References 33 publications

The Use of Intrathecal Midazolam in Humans: A Case Study of Process

The Use of Intrathecal Midazolam in Humans: A Case Study of Process

Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide

Hplc–dad Method for Studying the Stability of Solutions Containing Morphine, Dexamethasone, Haloperidol, Midazolam, Famotidine, Metoclopramide, and Dimenhydrinate

Contact Info

Product

Resources

About